GSK shareholders to vote on Novartis megadeal in December

Carly Helfand
Glaxo will soon have the chance to weigh in on an asset swap between GlaxoSmithKline and worth more than $ 20 billion.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS